Evaxion Biotech Doses First Patient in Phase I/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors

NEXT STORY
New Science for a New Virus: COVID Researchers Unveil Gaps in Our Understanding of the Respiratory System
PREV STORY
European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Everest Medicines Completes US$310 Million Series C Financing

author_avatar
NASDAQ Market News

NuGenerex Immuno-Oncology Submits Protocol, Data, and Manufacturing Information to FDA in Advance of the IND Submission

author_avatar
NASDAQ Market News

Positive clinical phase III results of vortioxetine in Japanese adults with Major Depressive Disorder

New clinical phase III data from a study conducted in Japan demonstrate the efficacy ...

author_avatar
NASDAQ Market News